All In Biotech

Drug Trial Radar · NCT01705977

Belimumab Assessment of Safety in SLE

A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab

Last checked: Nov 20, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 4,019 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,019

Actual

Start

Nov 27, 2012

Primary completion

Jul 30, 2018

Study completion Aug 10, 2022

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 15, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to further enhance the existing knowledge regarding the side effects of belimumab when given with other lupus medicines to adults with active systemic lupus erythematosus (SLE). This study mainly focuses on collecting information on serious events that are not that common or may only be seen with long-term treatment. These events include death, serious infections and other infections of interest, cancers, serious mental health problems, including depression and suicide, and serious infusion and hypersensitivity reactions. This study is being done to help understand if treatment with belimumab increases the risk for these types of events. This study will also see if patients receiving belimumab with other lupus medicines can reduce their use of steroids, such as prednisone, over 1 year.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Placebo plus standard therapyBiological

    Placebo plus standard therapy

  • Belimumab 10 mg/kg plus standard therapyBiological

    Belimumab 10 mg/kg plus standard therapy

  • Standard therapyOther

    Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Deaths - On Treatment Period (Week 52)Time frame: Up to Week 52 (On-treatment period)
  2. Number of Participants Who Reported Protocol Defined Adverse Events of Special Interest (AESI): On-treatment Period (Week 52)Time frame: Up to Week 52 (On-treatment period)
  3. Number of Participants With Serious Adverse Events (SAEs) Reported During On-treatment Period (Week 52)Time frame: Up to Week 52 (On-treatment period)

Locations

250 sites in 33 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Anniston, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Glendale, Arizona

  • GSK Investigational Site

    Mesa, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Covina, California

  • GSK Investigational Site

    Huntington Beach, California

  • GSK Investigational Site

    La Mesa, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Murrieta, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Leandro, California

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Cedar Rapids, Iowa

  • GSK Investigational Site

    Saint Clair Shores, Michigan

  • GSK Investigational Site

    West Bloomfield, Michigan

  • GSK Investigational Site

    Jackson, Mississippi

  • GSK Investigational Site

    Kalispell, Montana

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Chapel Hill, North Carolina

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Columbus, Ohio

  • GSK Investigational Site

    Duncansville, Pennsylvania

  • GSK Investigational Site

    Wyomissing, Pennsylvania

  • GSK Investigational Site

    Orangeburg, South Carolina

  • GSK Investigational Site

    Rock Hill, South Carolina

  • GSK Investigational Site

    Summerville, South Carolina

  • GSK Investigational Site

    Hixson, Tennessee

  • GSK Investigational Site

    Memphis, Tennessee

  • GSK Investigational Site

    Cypress, Texas

  • GSK Investigational Site

    Dallas, Texas

Showing 40 of 250 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.